Affordable Access

deepdyve-link
Publisher Website

Type II cGMP-dependent protein kinase inhibits ligand‑induced activation of EGFR in gastric cancer cells.

Authors
  • Jiang, Lu
  • Chen, Yongchang
  • Li, Yueying
  • Lan, Ting
  • Wu, Min
  • Wang, Ying
  • Qian, Hai
Type
Published Article
Journal
Molecular Medicine Reports
Publisher
Spandidos Publications
Publication Date
Apr 01, 2014
Volume
9
Issue
4
Pages
1405–1409
Identifiers
DOI: 10.3892/mmr.2014.1942
PMID: 24534906
Source
Medline
License
Unknown

Abstract

Our previous data demonstrated that type II cGMP‑dependent protein kinase (PKG II) inhibited epidermal growth factor (EGF)-induced MAPK/ERK/JNK‑mediated signal transduction through inhibiting the phosphorylation/activation of the epidermal growth factor receptor (EGFR). Since the EGFR also binds with several other ligands as well as EGF, the present study was designed to investigate whether PKG II inhibited transforming growth factor-α (TGF-α), betacellulin (BTC) and epiregulin (EPR) induced phosphorylation/activation of the EGFR and consequent MAPK/ERK‑mediated signaling. The human gastric cancer cell line AGS, was infected with adenoviral constructs encoding cDNA of PKG II (Ad-PKG II) to increase the expression of PKG II and was treated with 8-pCPT-cGMP to activate the kinase. Western blotting was applied to detect the phosphorylation of EGFR and MAPK/ERK. The results demonstrated that treatment with EGF (100 ng/ml, 5 min), TGF-α (100 ng/ml, 5 min), BTC (100 ng/ml, 5 min) and EPR (100 ng/ml, 5 min) increased the tyrosine (tyr) 1068 phosphorylation of the EGFR and the threonine (thr) 202/tyr 204 phosphorylation of MAPK/ERK. Infecting the cells with Ad-PKG II and stimulating the kinase with 8-pCPT-cGMP efficiently inhibited the phosphorylation of the EGFR and MAPK/ERK induced by EGF, TGF-α, BTC and EPR. The results indicated that PKG II also inhibits the activation of the EGFR caused by diverse ligands of the receptor.

Report this publication

Statistics

Seen <100 times